Bristol-Myers Squibb Co. (BMY) reported Thursday a 12 percent increase in first-quarter profit, above Street estimates, boosted by higher sales, even as its blockbuster drug Plavix recorded lower sales. The Biopharmaceutical firm also maintained its fiscal 2012 earnings forecast.
Type 2 diabetes drug Onglyza/Kombiglyze, Arthritis drug Orencia as well as two other cancer drugs posted significant sales in the quarter, while the sales of its flagship anti-clogging drug Plavix, for which the company will lose exclusivity in May 2012, declined 4 percent.
For its first quarter, net earnings attributable to the company rose 12 percent to $1.10 billion or $0.64 per share from last year's $986 million or $0.57 per share. The earnings growth would have been 10 percent on an adjusted basis.
On average, 18 analysts polled by Thomson Reuters expected earnings of $0.63 per share for the quarter. Analysts' estimates typically exclude one-time items.
Bristol-Myers' net sales grew 5 percent to $5.25 billion, but came in below Wall Street analysts' estimate of $5.26 billion. U.S. net sales increased 6 percent to $3.5 billion and international net sales grew 2 percent to $1.8 billion.
In the quarter, Plavix's sales dropped 4 percent to $1.69 billion, while the decline was 1 percent in the U.S. Sales of hypertension drugs Avapro/Avalide also declined 29 percent.
However, sales of Onglyza/Kombiglyze climbed 99 percent to $161 million and sales of cancer drug Sprycel improved 34 percent to $271 million. Orencia's sales grew 28 percent and that of chronic hepatitis B drug Baraclude improved 18 percent from a year ago. Cancer drug Yervoy, which was approved by the FDA in March 2011, had sales of $154 million in the quarter.
The company's gross margin was 75.2 percent in the quarter, higher than 73.2 percent in the same period a year ago.
In the quarter, marketing, selling and administrative expenses increased 8 percent, while advertising and product promotion spending and research and development expenses declined.
Chief Executive Officer Lamberto Andreotti said, "We reported good financial performance at both the top and bottom lines, a positive opinion in Europe on FORXIGA for the treatment of type 2 diabetes and the presentation of important new clinical data from the Company's HCV franchise."
In February, the company completed its $2.5 billion acquisition of Inhibitex, Inc., a clinical-stage biopharmaceutical company. Bristol-Myers noted that Inhibitex's lead compound, INX-189, a nucleotide polymerase inhibitor in Phase II development, is part of a class of antivirals that may play a critical role as the backbone of future direct-acting antiviral-only combination approached to HCV treatment.
Looking ahead, Bristol-Myers continues to expect fiscal 2012 earnings per share between $1.90 and $2, while 21 analysts project full-year earnings of $1.97 per share.
The company previously had said that its worldwide sales for the year would be between $17.2 billion and $18.2 billion, assuming that worldwide sales of Plavix to be approximately $2.7 billion. Analysts currently expect sales of $18.02 billion for the year.
Bristol-Myers shares are currently trading at $33.75, down $0.54 or 1.57 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.